Navigation Links
FDA Clears a Test for Ovarian Cancer
Date:9/11/2009

Test can help identify potential malignancies, guide surgical decisions

SILVER SPRING, Md., Sept. 11 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today cleared a test that can help detect ovarian cancer in a pelvic mass that is already known to require surgery. The test, called OVA1, helps patients and health care professionals decide what type of surgery should be done and by whom.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

OVA1 identifies some women who will benefit from referral to a gynecological oncologist for their surgery, despite negative results from other clinical and radiographic tests for ovarian cancer. If other test results suggest cancer, referral to an oncologist is appropriate even with a negative OVA1 result.

OVA1 should be used by primary care physicians or gynecologists as an adjunctive test to complement, not replace, other diagnostic and clinical procedures.

OVA1 uses a blood sample to test for levels of five proteins that change due to ovarian cancer. The test combines the five separate results into a single numerical score between 0 and 10 to indicate the likelihood that the pelvic mass is benign or malignant.

OVA1 is intended only for women, 18 years and older, who are already selected for surgery because of their pelvic mass. It is not intended for ovarian cancer screening or for a definitive diagnosis of ovarian cancer. Interpreting the test result requires knowledge of whether the woman is pre- or post-menopausal.

The American College of Obstetricians and Gynecologists and the Society of Gynecologic Oncologists published recommendations in 2002 for the role of generalist obstetrician-gynecologists in the earl
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. U.S. Food and Drug Administration Clears Way for Multi-Center Clinical Trial of IDEV Technologies SUPERA Peripheral Stent
2. FDA Clears the Pathwork(R) Tissue of Origin Test for Hard-To-Identify Tumors
3. FDA Clears ExAblate Fertility Enhancement Study in Women With Uterine Fibroids
4. FDA Clears Advanced Test for Monitoring Metastatic Colorectal Cancer
5. Cancer Treatment Centers of America(R) Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells
6. Oasmia: FDA Grants Paclical(R) Orphan Drug Designation for Ovarian Cancer in the USA
7. Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results
8. Pivotal Data Published For First Biomarker Combination Test to Determine Risk of Ovarian Cancer in Women Who Present With Pelvic Mass
9. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
10. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
11. Abeome and Cato Research to Collaborate on Ovarian Cancer Therapeutic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... -- Unilife Corporation (NASDAQ: UNIS, ASX: UNS), a designer, manufacturer ... that its Chairman and CEO, Alan Shortall , ... Annual Healthcare Conference at the New York Palace Hotel ... The conference presentation will be broadcast ... To listen, please go to: http://ir.unilife.com/events.cfm . An ...
(Date:11/26/2014)... THOUSAND OAKS, Calif. and LONDON ... AMGN ) and AstraZeneca (NYSE: AZN ) today ... trial evaluating two doses of brodalumab in more than 1,800 ... compared with both Stelara ® (ustekinumab) and placebo at ... the brodalumab weight-based analysis group were each shown to be ...
(Date:11/26/2014)... SAN DIEGO , Nov. 25, 2014 Halozyme ... at the Piper Jaffray Healthcare Conference in New ... p.m. EDT/10:00 a.m. PDT . Dr. Helen Torley ... overview. The presentation will be webcast through the ... and a recording will be made available for 90 days ...
Breaking Medicine Technology:Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2
... the Study of the ... Liver Annual Meeting -, SAN FRANCISCO, April ... 2 study of its lead,compound, MitoQ(R) (mitoquinone) in liver disease. The results ... of the Liver,(EASL) Annual Meeting, being held April 23 - 27 in ...
... at the 10th Annual Superbugs and Superdrugs Conference on ... ... Mass., April 10 Enanta Pharmaceuticals, a,leader in the development ... breakthrough research program to,evaluate a new macrolide-related drug class, Bicyclolides, ...
Cached Medicine Technology:Antipodean Pharmaceuticals Announces Completion of Phase 2 Study of Lead Compound MitoQ(R) 2Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA 2Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA 3
(Date:11/26/2014)... Dr. Rod J. Rohrich, Dallas ... the Department of Plastic Surgery at UT Southwestern ... grafting, and modern lift-and-fill facelifts before colleagues at ... by the American Society of Plastic Surgeons (ASPS). ... structure were explored in detail during Dr. Rohrich's ...
(Date:11/26/2014)... By Amy Norton ... -- While people have long believed their dogs understand what ... meaning and emotion of words in a human-like way. ... of human speech -- including the actual content and the ... team,s findings give a deeper insight into the canine brain, ...
(Date:11/26/2014)... Nov. 26, 2014 (HealthDay News) -- More than half ... their thinking and memory skills, a new study suggests. ... Neurology , "approximately 1.8 million Americans over the age ... of their cognitive [mental] abilities," study author Dr. Vikas ... Ann Arbor, said in a journal news release. ...
(Date:11/26/2014)... Deptford, NJ (PRWEB) November 26, 2014 ... and Lourdes Cardiology have launched a partnership designed ... readmission rates for congestive heart failure (CHF) patients ... Deptford Center staff and Lourdes Cardiology team will ... developed and supervised protocols. This partnership pairs the ...
(Date:11/26/2014)... German scientists say carbon-based synthetic molecules used ... that looks and acts similar to asbestos-induced mesothelioma. Surviving ... research. Click here to read it now. ... Experimental Medicine in Hannover injected 500 lab rats with ... eventually developed mesothelioma , how quickly it developed ...
Breaking Medicine News(10 mins):Health News:Dr. Rod J. Rohrich Discusses Facelifts at ASPS Annual Assembly 2Health News:Dr. Rod J. Rohrich Discusses Facelifts at ASPS Annual Assembly 3Health News:Your Dog Really Is Listening to You 2Health News:Your Dog Really Is Listening to You 3Health News:Too Few Americans Undergo Dementia Screening 2Health News:Advanced Heart Failure Recovery Program comes to Deptford Center for Rehabilitation and Healthcare 2Health News:Advanced Heart Failure Recovery Program comes to Deptford Center for Rehabilitation and Healthcare 3Health News:Multi-walled Nanotubes Linked to Mesothelioma in New Study, According to Surviving Mesothelioma 2
... , , NASHVILLE, ... $11.6 and $18 billion in diagnostic imaging costs over the ... program similar to those used in the private sector. Currently, ... billions of dollars. According to an independent analysis released today ...
... , , , ... , , FAIRFAX, Va., July 16 ... a cancer survivor in the Chicago area who has dedicated his or ... winner of the Survivor Circle Award will receive $1,000 and be honored ...
... , The hospital is the highest-rated Illinois ... , CHICAGO, July 16 Northwestern Memorial Hospital is ... ranked in Illinois -- as part of U.S. News & World Report,s 2009 ... guide evaluated 4,861 medical centers nationwide and 174 were chosen and ranked according ...
... get LASIK, researchers say , THURSDAY, July 16 (HealthDay ... surgery may benefit from implantable lenses made of a ... LASIK "has gained widespread popularity as a safe and ... with high [severe] myopia or thin corneas face some ...
... , , , ... www.STDTestExpress.com ) offers leading direct-to-consumer testing services for sexually ... on the Internet to have partnered with a telemedicine network ... to order these specialty tests, discuss STD symptoms, review test ...
... 16 Enigma Diagnostics Limited, the decentralized and point-of-care molecular ... license agreements with Roche Molecular Systems, Inc. (RMS). , ... July 2009, provide Enigma full access under patents owned or ... PCR chemistry and melt analysis and will allow Enigma to ...
Cached Medicine News:Health News:Radiology Benefit Management Could Save Medicare up to $18 Billion Over 10 Years 2Health News:Radiology Benefit Management Could Save Medicare up to $18 Billion Over 10 Years 3Health News:Award Honors Chicago Cancer Survivor Who Gives Back 2Health News:Award Honors Chicago Cancer Survivor Who Gives Back 3Health News:Award Honors Chicago Cancer Survivor Who Gives Back 4Health News:Northwestern Memorial Among America's Best Hospitals in 11 Clinical Specialties According to U.S. News' 2009 Rankings 2Health News:Northwestern Memorial Among America's Best Hospitals in 11 Clinical Specialties According to U.S. News' 2009 Rankings 3Health News:New Option for Correcting Nearsightedness 2Health News:STD Test Express Offers Free Doctor Consultations With Every STD Test 2Health News:Enigma Diagnostics Announces Signing of Patent Licenses With Roche Molecular Systems, Inc. 2
Shandon Slide File Storage System...
Shandon Plastic Slide Folders...
Shandon Microscope Slide Cabinet with Drawers...
... containing over 330 species of microorganisms ... Compact offers enhanced identification capabilities. In ... to 14 hours), it identifies the ... production areas and final products., Therefore, ...
Medicine Products: